INS and metabolic dysfunction-associated steatotic liver disease: While current clinical management of NAFLD primarily relies on lifestyle modifications and metabolic regulation interventions—including insulin sensitizers, antioxidants, and lipid-lowering agents—these approaches can delay disease progression but rarely reverse hepatic steatosis and fibrosis.